Signup to have metrics tracked for this article

By signing up, social media discussions about Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. will be collected and displayed on PubHawk. We'll also notify you by email on a monthly basis of any new updates captured on platforms like YouTube, Twitter/X, Bluesky, Facebook, LinkedIn, and more.
Your identifiable personal information will never be sold or shared to directly target you.

Example of Metrics tracking for this article: